GlassScriptPhysician profile
Kelly Patterson
NPI 1841681723
$1,744.76
in general payments reported to CMS, 2019-2025
20 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.71 · 2022: $275 · 2023: $584 · 2024: $575 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $569.04 | 2021-2025 | Lifevest |
| Philips North America LLC | $133.31 | 2023-2025 | Ecc Solutions, (Ck4) Mcot, (Ck7) Extended Holter |
| Edwards Lifesciences Corporation | $130.12 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.11 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.12 | 2022-2024 | Jardiance |
| Irhythm Technologies, INC. | $91.56 | 2024 | Zio Monitor, Zio Xt Patch |
| Merck Sharp & Dohme LLC | $91.19 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $61.93 | 2023 | |
| Novartis Pharmaceuticals Corporation | $60.01 | 2024 | |
| Janssen Pharmaceuticals, INC | $57.24 | 2022-2024 | Xarelto |
| Abbott Laboratories | $49.17 | 2023 | Cardiomems |
| Alnylam Pharmaceuticals INC. | $48.80 | 2024-2025 | Onpattro |
| Amgen INC. | $48.37 | 2023-2024 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $44.00 | 2024 | Arcalyst |
| Abiomed | $37.55 | 2024 | Impella |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $17.57 | 2023 | Arcalyst |
| Cvrx, INC. | $16.87 | 2022 | |
| Boston Scientific Corporation | $16.16 | 2024 | Watchman Flx |
| Glaxosmithkline, LLC. | $16.06 | 2025 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $15.58 | 2023 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.